3//SEC Filing
Atlas Venture Associates IX, L.P. 3
Accession 0000899243-17-025151
CIK 0001701108other
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 7:50 PM ET
Size
14.3 KB
Accession
0000899243-17-025151
Insider Transaction Report
Form 3
Atlas Venture Associates IX, LLC
10% Owner
Holdings
Junior Preferred Stock
→ Common Stock (245,605 underlying)Series A Preferred Stock
→ Common Stock (246,272 underlying)Series C Preferred Stock
→ Common Stock (513,318 underlying)Series B Preferred Stock
→ Common Stock (328,992 underlying)- 42,781
Common Stock
Atlas Venture Fund IX, L.P.
10% Owner
Holdings
- 42,781
Common Stock
Junior Preferred Stock
→ Common Stock (245,605 underlying)Series B Preferred Stock
→ Common Stock (328,992 underlying)Series A Preferred Stock
→ Common Stock (246,272 underlying)Series C Preferred Stock
→ Common Stock (513,318 underlying)
Atlas Venture Associates IX, L.P.
10% Owner
Holdings
- 42,781
Common Stock
Series B Preferred Stock
→ Common Stock (328,992 underlying)Series A Preferred Stock
→ Common Stock (246,272 underlying)Junior Preferred Stock
→ Common Stock (245,605 underlying)Series C Preferred Stock
→ Common Stock (513,318 underlying)
Footnotes (7)
- [F1]The number of shares reported reflects a 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.
- [F2]The shares of Junior preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F3]Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.
- [F4]The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F5]The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F6]The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F7]The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001671208
Filing Metadata
- Form type
- 3
- Filed
- Oct 31, 8:00 PM ET
- Accepted
- Nov 1, 7:50 PM ET
- Size
- 14.3 KB